Insulin resistance (IR) is a central pathophysiologic defect in type 2 diabetes mellitus (T2DM). The present study investigated whether the natural alkaloid evodiamine (Evo) can alleviate IR and sought to elucidate the molecular mechanisms involved. The authors combined network pharmacology, molecular docking and dynamics, and in vitro cell experiments to identify Evo targets and test effects on key proteins and glucose metabolism pathways implicated in IR.
The investigators used multiple biomedical databases to identify candidate bioactive components and molecular targets of evodiamine. From those data, they compiled 122 Evo-associated targets. Separately, they collected targets associated with insulin resistance and performed an intersectional analysis to identify overlapping targets. Thirty-seven targets were common to both Evo and IR datasets. Network analysis highlighted several hub proteins among the intersecting set, notably AKT1, STAT3, SRC, and PTGS2.
The study applied molecular docking to evaluate potential physical interactions between Evo and prioritized target proteins, followed by molecular dynamics (MD) simulations to further assess the stability of those predicted interactions. Docking and MD results were used to support the relevance of the identified targets and to prioritize proteins for experimental validation. The abstract reports that MD analysis confirmed interactions between Evo and key proteins; specific docking scores and MD parameters are not provided in the abstract.
Functional validation experiments were performed in an insulin-resistant HepG2 cell model (IR-HepG2). The CCK-8 (cell counting kit-8) assay was used to evaluate the effects of Evo on cell viability prior to metabolic and signaling assays. The abstract indicates the CCK-8 assay was employed, but it does not provide numerical viability results, nor does it list the Evo concentrations or exposure times used for the viability or subsequent functional assays.
Glucose uptake and glucose production were quantified to determine Evo's effect on hepatocyte glucose handling under insulin-resistant conditions. Compared with control cells, IR-HepG2 cells demonstrated lower glucose consumption and higher glucose production. Administration of Evo increased glucose consumption and decreased glucose production in the IR model. Metformin was included as a positive control; the abstract reports statistically significant differences in glucose consumption and production between Evo- and metformin-treated IR-HepG2 cells, but specific values and statistical metrics are not detailed in the abstract.
To probe signaling mechanisms, the authors measured total and phosphorylated forms of proteins in the IRS-1/PI3K/AKT cascade by Western blot. In the IR-HepG2 model, phosphorylated PI3K (p-PI3K) and phosphorylated AKT (p-AKT) levels were decreased versus controls. Evo treatment dose-dependently restored p-PI3K and p-AKT expression in IR-HepG2 cells, with effects resembling those observed with metformin.
Notably, phosphorylated IRS-1 (p-IRS-1) was elevated in the model group relative to controls; Evo reduced p-IRS-1 levels in IR-HepG2 cells. The authors report that metformin did not significantly reduce p-IRS-1 in this experimental setup, distinguishing Evo’s effect on this upstream regulatory node.
Immunofluorescence assays were used to visualize and quantify expression of IRS-1, p-IRS-1, and GLUT4 in IR-HepG2 cells. Findings from immunofluorescence were consistent with Western blot results: Evo decreased p-IRS-1 and increased GLUT4 expression in insulin-resistant hepatocytes. These results support a model in which Evo promotes glucose uptake and reduces gluconeogenic output at least in part via effects on the IRS-1/PI3K/AKT/GLUT4 axis.
Together, these experimental layers support the conclusion that Evo’s anti-IR actions are plausibly mediated by modulation of the IRS-1/PI3K/AKT/GLUT4 signaling axis.
The abstract does not provide experimental details necessary to fully assess reproducibility and clinical translation. Specifically, the abstract does not report Evo concentrations, exposure durations, quantitative viability results from the CCK-8 assay, exact glucose assay values, or statistical test details. Docking scores, MD simulation parameters, and sample sizes for cell experiments are also not reported in the abstract. These omissions limit appraisal of effect size, dose–response relationships, and methodological rigor from the abstract alone.
Using a combined computational and experimental approach, the authors provide converging evidence that evodiamine can mitigate insulin resistance in HepG2 cells and that modulation of the IRS-1/PI3K/AKT/GLUT4 pathway is a likely mechanism. The study supports further exploration of Evo as a candidate for IR-targeted therapeutic development but additional detailed methodological reporting and in vivo validation will be required before translational conclusions can be drawn.